Across TCGA pan-cancer cohorts, RPS4XP21 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPS4XP21 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RPS4XP21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS4XP21 expression acts as an unfavorable survival marker.

CESC and SKCM are the cancer types where RPS4XP21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.261	0.798	.006	12	view →
SKCM	OS	Median	All	0.245	0.781	.024	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RPS4XP21 tumor-vs-normal RNA expression · all RPS4XP21 data types